TICKERNERD
Menu
SNYRSNYRHealthcare · Medical Distribution

SNYR Stock Forecast: Synergy CHC Corp. Price Predictions for 2026-2027

Last close, 17 Sept 2026
$0.09

The 1 Wall Street analysts covering Synergy CHC Corp. hold a median 12-month price target of $3.75 — +4043.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 56 of 100 as at 17 Sept 2026 — in the upper half.

Market cap
$1.4M
Ticker Nerd rank
56 / 100
Median analyst target
$3.75
Analysts covering
1
Revenue$5.5M−32.8% y/y
Operating income−$567K
Net income−$2.6M
Free cash flow−$2.0M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Ticker Nerd rank

SNYR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Synergy CHC Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Sept 2026
56 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
100
Accruals
90
Revisions
58
Issuance
55
Value
48
Quality
40
Growth
29
Momentum
27
Volatility
26

Size (100): Smaller than most of the companies we track.

Volatility (26): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SNYR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SNYR, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $3.75Median $3.75High $3.75

The green dot is the last close — the median target sits +4043.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
10 June 2026Ascendiant CapitalMaintainsBuy—
10 June 2026Ascendiant CapitalMaintainsBuy$5.50 → $3.75
14 Apr 2026Ascendiant CapitalMaintainsBuy—
2 Feb 2026Ascendiant CapitalInitiatesBuy—
14 Nov 2025Roth CapitalMaintainsBuy—
21 Jan 2025Roth MKMInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SNYR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

SNYR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−161.3%
Analysts raising
0
Analysts cutting
1
Fundamentals

Synergy CHC Corp. (SNYR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.9×

Cheaper than 67% of US stocks

Price / sales
0.0×

Cheaper than 98% of US stocks

Price / book
−0.0×

Cheaper than 93% of US stocks

EV / EBITDA
−2.6×

Cheaper than 74% of US stocks

Growth & margins
Revenue growth (YoY)
−32.8%

Higher than 8% of US stocks

Earnings growth (YoY)
−32.8%

Higher than 15% of US stocks

Gross margin
72.3%

Higher than 85% of US stocks

Operating margin
−10.3%

Higher than 24% of US stocks

Net margin
−57.0%

Higher than 9% of US stocks

Returns & dividend
Return on equity
53.4%

Higher than 93% of US stocks

Return on assets
−62.0%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Synergy CHC Corp. (SNYR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Synergy CHC Corp. has a market value of $1.4M and an enterprise value of $28.3M.

  • Revenue in the twelve months to 31 Mar 2026: $27.7M. The latest quarter shrank 32.8% year on year.

  • Net income over the same four quarters: −$15.8M, a −57.0% net margin.

  • Free cash flow in the twelve months to 31 Mar 2026: −$3.8M.

  • Shares outstanding: 11.3M.

  • Trailing P/E: 3.9×; forward P/E: 0.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Synergy CHC Corp. employs 28 people — $989K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 21 Sept 2026

Data provided by Twelve Data

Peers

SNYR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Distribution
CompanyMarket capTKN rank
SNYRSynergy CHC Corp.$1.4M
56
MEDSDataMeds AI, Inc.$11.4M
16
HELPCybin, Inc.*$1.4M
45
BBLGBone Biologics Corp.*$1.4M
27
MNDRMobile-health Network Solutions*$1.5M
13
PFSAProfusa, Inc.*$1.2M
12
COSMCosmos Health, Inc.$32.0M
18

* Nearest Healthcare names by size — few medical distribution companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Synergy CHC Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SNYR news & analysis

Synergy CHC Corp. Announces Receipt of Nasdaq Letter

GlobeNewsWire · 21 Aug 2026negative

Synergy CHC Corp. disclosed that it received a notice from Nasdaq on August 20, 2026, indicating the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because it delayed filing its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 with the SEC.

Why it matters — A Nasdaq non-compliance notice over a delayed SEC filing raises potential listing-status and regulatory concerns for SNYR shareholders.

FAQ

Frequently asked questions about SNYR stock

What is the SNYR stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Synergy CHC Corp. have a median 12-month price target of $3.75, with estimates ranging from $3.75 to $3.75. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SNYR stock a buy right now?

Of the 1 analysts covering Synergy CHC Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Synergy CHC Corp. 56 out of 100 across roughly 4,600 US stocks as at 17 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SNYR?

As at 17 Sept 2026, Synergy CHC Corp. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (100 of 100).

Will SNYR stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +4043.6% from the last close, and Ticker Nerd's factor model ranks Synergy CHC Corp. 56 out of 100 as at 17 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SNYR stock forecast for 2030?

No analyst covering Synergy CHC Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SNYR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.75 to $3.75 over the next 12 months.

What does Synergy CHC Corp. do?

Synergy CHC Corp. Common Stock represents ownership in Synergy CHC Corp., a consumer health and wellness company focused on branded products for everyday use.

What is the latest news on SNYR?

The most recent item we track (GlobeNewsWire, 21 Aug 2026): "Synergy CHC Corp. Announces Receipt of Nasdaq Letter". Synergy CHC Corp. disclosed that it received a notice from Nasdaq on August 20, 2026, indicating the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because it delayed filing its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 with the SEC.

Company

About Synergy CHC Corp.

Synergy CHC Corp. Common Stock represents ownership in Synergy CHC Corp., a consumer health and wellness company focused on branded products for everyday use. The company develops and markets a range of health care, beauty, and lifestyle offerings, including nutritional supplements, over-the-counter products, hand care items, and wellness accessories. Its portfolio includes products sold under brands such as FOCUSfactor, Flat Tummy, Hand MD, Neuragen, and UrgentRx, serving consumers seeking convenience-focused personal care and self-care solutions. Synergy CHC Corp. distributes its products through club, mass-market, drug, and other retail channels across the United States, Canada, Mexico, and select international markets. The common stock serves as the company’s equity security in the public market and reflects its position within the consumer staples and personal care products segment.

CEO Mr. Jack Ross · 28 employees · United States · https://synergychc.com